{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:48:07Z","timestamp":1790534887668,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.kint.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T08:54:47Z","timestamp":1553072087000},"page":"747-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward"],"prefix":"10.1016","volume":"95","author":[{"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Frimat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.12.006_bib1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0140-6736(16)31331-9","article-title":"Roadmap for cardiovascular prevention trials in chronic kidney disease","volume":"388","author":"Rossignol","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.12.006_bib2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.12.006_bib3","article-title":"Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints","author":"Rossignol","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2018.12.006_bib4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/HYPERTENSIONAHA.109.144899","article-title":"Blood pressure and mortality among hemodialysis patients","volume":"55","author":"Agarwal","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2018.12.006_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2013.09.057","article-title":"Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis","volume":"63","author":"Pitt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.kint.2018.12.006_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.12.006_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.12.006_bib8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A\u00a0randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.12.006_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal syndrome revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819300067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819300067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:51:18Z","timestamp":1758761478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819300067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0085253819300067"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.12.006","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.08.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.11.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}